Abstract
Since late 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, better known as COVID-19) has rapidly spread worldwide. The primary pathophysiology by which COVID-19 leads to severe lung damage is cytokine releasing syndrome (CRS), which can cause death. Therefore, removing cytokines via therapeutic plasma exchange or hemoperfusion could be a therapeutic approach to treat CRS. However, hemoperfusion or therapeutic plasma exchange could alter the effectiveness of concomitant medications. Thus, concomitant medication doses might need to be adjusted to prevent their elimination via therapeutic plasma exchange or hemoperfusion, thus ensuring that these medications remain effective. This narrative review investigates the elimination status of current medications used to manage COVID-19 during hemoperfusion and therapeutic plasma exchange, with a focus on their pharmacokinetic profiles.
Keywords: COVID-19; Elimination; Hemoperfusion; Therapeutic plasma exchange.
【저자키워드】 COVID-19, Elimination, Hemoperfusion, Therapeutic plasma exchange, 【초록키워드】 SARS-CoV-2, coronavirus, Cytokines, cytokine, severe acute respiratory syndrome Coronavirus, Elimination, Hemoperfusion, Spread, pathophysiology, plasma exchange, Effectiveness, death, plasma, respiratory, medication, CRS, pharmacokinetic, Therapeutic approach, dose, Therapeutic plasma exchange, lung damage, leads, focus, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, profiles, Concomitant medication, treat, concomitant medications, cytokine releasing syndrome, Alter, Prevent, effective, adjusted, 【제목키워드】 therapeutic, plasma, medication, Evaluating,